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Abstract: YueF is a novel putative tumor suppressor gene that can inhibit proliferation and 
induce apoptosis in hepatoma cells, but its role in renal cell carcinoma (RCC) remains 
unclear. Here, we examined the expression of the YueF gene in RCC tissues and the effect 
of  YueF  on  cell  proliferation  in  RCC  786-0  cells.  The  results  showed  that  YueF  was 
expressed at high levels in normal kidney tissues and cell lines but was reduced or absent 
in RCC tissues and 786-0 cells. Lentivirus-mediated YueF overexpression in RCC 786-0 
cells caused cell-cycle arrest in the G1 phase and dramatically reduced proliferation in 
culture. YueF overexpression resulted in increased protein levels of p53 and p21
WAF1/Cip1, 
whereas the protein levels of cyclin D1 and pRb were decreased. The proliferation defects 
caused  by  YueF  overexpression  could  be  partially  rescued  by  the  expression  of  p21 
siRNA.  These  findings  suggest  a  critical  role  for  p21  in  the  YueF-induced  growth 
inhibition of 786-0 cells and provide novel insights into the mechanism underlying the 
tumor-suppressive action of YueF. 
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1. Introduction 
Renal  cell  carcinoma  (RCC)  is  the  most  common  type  of  kidney  cancer  and  follows  an 
unpredictable  disease  course [1];  it  is  the  most  malignant  tumor  of  the  kidney  and  accounts  for 
approximately 2–3% of all adult cancers in Western countries. Moreover, the morbidity and mortality 
associated with renal carcinoma has steadily increased over the past 20 years. Histopathologically, 
RCC is classified into four subtypes, with 80% of cases consisting of the clear cell subtype [2]. Due to 
its insidious onset, patients frequently exhibit advanced disease at the time of clinical diagnosis; drugs 
and  newly  discovered  markers  have  been  unable  to  significantly  increase  the  survival  of  these 
patients [3].  Therefore,  additional  research  is  required  to  identify  specific  genes  that  might  play 
important roles in RCC carcinogenesis. 
YueF  (GenBank  accession  number:  BC006131)  is  a  putative  tumor  suppressor  gene  that  is 
expressed in hepatomas [4]. It was initially discovered by Huang et al. [4,5] using a yeast two-hybrid 
method aimed at identifying Hepatitis B virus X protein (HBx)-interacting proteins. YueF is highly 
expressed in  the cytoplasm  of normal  cells  and tissues, including liver, lung, bladder, myocardial 
tissue, and intestine; however, it is detected at low levels in corresponding tumor tissues, including 
liver, lung, and bladder cancers. Overexpression of YueF can inhibit the proliferation of hepatocellular 
carcinoma (HCC) cells, induce apoptosis in vitro and suppress the HCC tumorigenicity in nude mice in 
vivo, indicating that YueF might be a novel candidate gene for tumor suppression in tumorigenesis. 
However, the biological role and the mechanism of YueF action in renal cell carcinoma (RCC) are 
largely unknown. 
We investigated not only YueF expression in RCC tissues and corresponding normal tissues but 
also  studied  the  role  of  YueF  in  the  proliferation  of  RCC  cells.  Our  data  indicated  that  YueF 
expression decreased in RCC tissues and 786-0 cells. YueF overexpression resulted in increased levels 
of  p53  and  p21
WAF1/Cip1  protein  expression  and  a  decreased  level  of  cyclin  D1  expression  and 
subsequently induced inhibition of cell growth in 786-0 cells. The proliferation defects caused by 
YueF overexpression can be partially rescued with p21 siRNA. This study is the ﬁrst to demonstrate 
that YueF modulates cell growth via the regulation of the p21
WAF1/Cip1 pathway in renal cell carcinoma. 
2. Materials and Methods 
2.1. Human Tissue Preparation 
Tissue samples from eight human renal cell carcinomas and adjacent normal tissues were obtained 
after nephrectomy in RCC patients (2 females and 6 males) and examined by a pathologist. All the 
eight RCC samples are clear cell subtype, and all the adjacent tissue samples are normal, without 
fibrosis or other non-neoplastic changes. Four tumors were in stage I, three in stage II and one in stage 
III. All tissue samples were immediately dissected, frozen in liquid nitrogen and stored at −80 ﾰC. 
Tissue samples (1 g) were washed with normal saline (NS) to remove cell debris and any remaining 
blood before trituration with liquefacient nitrogen and subsequent homogenization in lysis buffer (9 M 
Urea, 4% CHAPS, 65 mM DTT, Rose’s enzyme inhibitor cocktail); after being completely dissolved 
by ultrasonic fragmentation, the homogenates were centrifuged at 100,000 g for 10 min at 4 ° C. The Int. J. Mol. Sci. 2011, 12                         
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supernatants were kept in small aliquots at −80 ﾰC. The total protein concentration was determined 
with the BCA method. 
2.2. Generation of Recombinant Lentivirus 
Total  RNA  was  isolated  from  normal  human  tissue  using  TRIzol  TM  Reagent  (GIBCO, 
Invitrogen);  RT-PCR  was  performed  using  a  First  Strand  cDNA  Synthesis  Kit  (MBI,  Fermentas, 
Lithuania). The YueF gene was ampliﬁed with PCR (Takara, Tokyo, Japan). The following specific 
primers were use: sense primer 5' TTGTCTAGAGCCACCATGGCTGCAAGTGGCCGAGGTCTCT 3' 
and  anti-sense  primer  5'  TATGCGGCCGCTCACATGCTCTTGAGGTCCCTAAAG  3',  which 
contained  Xbal  and  Not1  sites  (underlined),  respectively.  The  PCR  product  was  subcloned  into   
the  lentiviral  vector  pCDH-CMV-MCS-EF1-copGFP  (System  Biosciences,  Mountain  View,  CA, 
USA) to  generate pCDH-YueF. Then, the lentiviral  YueF plasmid was co-transfected into 293FT   
cells (Invitrogen, USA) along with three different packaging plasmids, pLP1, pLP2, and pLP/VSV-G, 
to generate lentivirus [6]. 
2.3. Cell Culture and Lentivirus Transduction 
Human  RCC  786-0  cells  were  cultured  in  Eagle’s  MEM  supplemented  with  10%  foetal   
bovine serum (FBS) (Hyclone, Logan, UT, USA) at 37 ° C under 5% CO2. The 786-0 cells were   
infected  at  a  multiplicity  of  infection  (MOI)  of  5  with  either  lentivirus  containing  the  YueF   
gene  (pCDH-YueF)  or  empty  virus  (EV)  containing  6  µ g/mL  of  polybrene  according  to  the   
manufacturer’s instructions. RT-PCR was used to examine gene expression in the 786-0 cells infected with 
pCDH-YueF.  The  following  primers  were  used  in  the  RT-PCR:  YueF  sense  primer 
5'-GGCGTGGAGACGAGATAA-3',  YueF  anti-sense  primer  5'-GAGGGTCAATGGCTAATGC-3', 
β-actin  sense  primer  5'-TCCCTGGAGAAGAGCTACGA-3',  and  β-actin  anti-sense  primer 
5'-TCGTCATACTCCTGCTTGCT-3'. 
2.4. Cell Proliferation Assay 
To examine the effect of YueF on cell growth, 786-0 cells were infected with either lentivirus 
containing the YueF gene (pCDH-YueF) or EV. The infected cells were seeded into 96-well plates and 
incubated  for  1  to  6  days.  Subsequently,  20  µL  of  a  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT, Sigma) solution (5 mg/mL, Sigma) was added to each well, and the plates 
were further incubated for 3 h. Crystals were dissolved in 0.04 M HCl in isopropanol. The absorbance 
at 490 nm was measured with a microplate reader (Bio Rad, Hercules, CA, USA). The experiments 
were independently repeated 3 times. 
2.5. p21 siRNA Transfection 
Transfecting cells with siRNA specific for human p21 achieved suppression of p21 in 786-0 cells. 
Control siRNA and p21 siRNA (and a pool of 3–4 individual siRNAs targeting different regions of 
p21  mRNA)  are  commercially  available  from  Ambion.  siRNA  transfection  was  performed  at  a 
working  concentration  of  25  nM  using  a  transfection  reagent  according  to  the  manufacturer’s Int. J. Mol. Sci. 2011, 12                         
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instructions. All experiments were independently performed at least 3 times, and similar results were 
obtained [7]. 
2.6. Western Blot Analysis 
Cell  extracts  were  obtained  using  lysis  buffer  containing  5  mmol/L  EDTA,  1  mmol/L 
phenylmethylsulfonyl ﬂuoride, 1 mmol/L dithiothreitol, 0.1 mmol/L leupeptin, 75 µmol/L pepstatin A, 
150 mmol/L NaCl, and 0.1% Triton X-100. The mixture was centrifuged for 30 min (15,000 rpm,   
4  ° C),  and  the  supernatant  was  collected  for  Western  blot  analysis.  Samples  (20  µg)  were 
electroblotted onto nitrocellulose membranes. An anti-YueF polyclonal antibody (Mr. Wu, State Key 
Laboratory of Virology, Wuhan University, China), and anti-human p53, p21, cyclin D1, CDK2, pRb 
(Ser780), and beta-actin polyclonal antibodies (Cell Signaling) were used as the primary antibodies; 
peroxidase-conjugated goat anti-rabbit or anti-mouse antibodies (Pierce) were used as the secondary 
antibodies.  Protein  bands  were  visualized  using  the  SuperSignal  West  Pico  Chemiluminescent 
Substrate (Pierce). 
2.7. Cell Cycle Analysis 
Cells grown in regular growth or serum-free media for 36 h were collected, fixed in methanol, and 
stained with PBS containing 10 μg/mL propidium iodide and 0.5 mg/mL RNase A for 15 min at   
37 ° C. The DNA content of the labeled cells was measured using the FACSCalibur flow cytometry 
system (BD Biosciences). Each experiment was performed in triplicate. 
2.8. Statistical Analysis 
Experiments were repeated three times and the results were expressed as the mean ±  SD. The 
Student’s  t-test  or  ANOVA  followed by  a post-hoc test  was  used  to  compare  the  values  of   
the  tumor  samples  to  those  of  the  control  samples.  A  value  of  P  <  0.05  was  considered  to  be 
statistically significant. 
3. Results 
3.1. Downregulated Expression of YueF Protein in Clinical RCC Tissues and RCC 786-0 Cells 
Western blot analysis was performed to detect YueF protein expression in RCC tissues. As shown 
in Figure 1, the expression of YueF was observed in the normal samples but was decreased by 10–95% 
of the normal tissue levels in the corresponding RCC tissue samples from 7 of the 8 tumors; however, 
no expression of YueF was observed in one of the RCC tumor samples (Figure 1A). It was also 
observed that the levels of YueF mRNA were high in the normal human renal proximal tubular cell 
line, HK2, but the expression levels were reduced in the RCC cell line, 786-0 (Figure 1B, C). These 
results  demonstrated  that  although  YueF  was  highly  expressed  in  normal  tissues  and  cells,  its 
expression was decreased in RCC tissues and cells. 
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Figure 1. Expression of YueF in RCC tissues and 786-0 cells. (A) Western blot showing 
YueF expression in  8 human RCC tissues (T) and corresponding normal  samples  (N), 
results were from 3 different gels. (B) (C) RT-PCR for YueF mRNA expression in human 
proximal tubule epithelial HK-2 cells and RCC 786-0 cells. β-actin was used as the internal 
control (* P < 0.05). 
 
3.2. Overexpression of YueF in RCC 786-0 Cells with Lentivirus 
To  study  the  biological  functions  of  YueF,  we  introduced  YueF  into  786-0  RCC  cells  using   
a lentivirus containing the YueF gene. The 786-0 cells were infected with either virus containing   
the  YueF  gene  (pCDH-YueF)  or  an  empty  virus  (EV);  RT-PCR  was  used  to  identify  YueF   
mRNA expression after infection. As shown in Figure 2, the infection efficiency was approximately 
100%  in  the  786-0  cells  (Figure  2A),  and  the  YueF  mRNA  level  was  significantly  higher  in 
YueF-overexpressing 786-0 cells (pCDH-YueF) compared to the empty virus (EV)-infected control 
786-0 cells (Figure 2B and C).   
Figure  2.  Restored  expression  of  YueF  in  RCC  786-0  cells.  (A)  Infection efficiency   
in  RCC  786-0  cells.  (B,  C)  Results  of  the  RT-PCR  assay  show  a  significantly   
increased  mRNA  level  of  YueF  in  YueF-overexpressing  786-0  cells  (pCDH-YueF) 
compared with empty virus-infected 786-0 cells (EV). β-actin was used as the internal 
control (* P < 0.05). 
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3.3. YueF Overexpression Inhibits the Proliferation of 786-0 Cells   
The effects of YueF overexpression on the proliferation 786-0 cells were examined. The growth 
curve results determined with an MTT assay showed that the overexpression of YueF (pCDH-YueF) 
significantly reduced the proliferation rate compared to the empty virus (EV)-infected cells (P < 0.05, 
Figure 3). 
Figure 3. Inhibition of cell proliferation in YueF-overexpressing 786-0 cells (pCDH-YueF) 
compared with empty virus-infected 786-0 cells (EV) (*P < 0.05). 
 
3.4. YueF Overexpression in 786-0 Cells Causes Cell Cycle Arrest at the G1 Phase 
Huang et al. [5] showed that overexpression of YueF inhibited hepatoma cell proliferation through 
the induction of apoptosis. Our results did not show apoptotic induction in the YueF-overexpressing 
786-0 cells (pCDH-YueF); therefore, we determined the cell cycle distribution. The S-phase population 
was markedly decreased, and the G1 population was significantly increased in the YueF-overexpressing 
786-0 cells (YueF) compared to the empty virus-infected 786-0 cells (EV) (P < 0.05). Neither YueF 
nor EV cells exhibited significant changes in the G2 population (Figure 4). 
Figure 4. Cell cycle arrest at the G1 phase was induced in the YueF-overexpressing 786-0 
cells (YueF) compared to the empty virus (EV)-infected 786-0 cells. (*P < 0.05)   
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3.5. YueF Overexpression Inhibits the Proliferation of 786-0 Cells Partly through p21 Upregulation 
Huang  et  al.  showed [5]  that  YueF  overexpression  enhanced  p53  promoter  activity  and  p53 
expression  in  hepatoma  cells.  Here,  we  also  showed  that  p53  expression  increased  in 
YueF-overexpressing cells (Figure 5A). To further explore how YueF overexpression induced cell 
cycle  arrest,  we  examined  the  relative  expression  levels  of  p21  (a  major  cyclin-dependent  kinase 
inhibitor) in  YueF-overexpressing 786-0 cells  (pCDH-YueF)  and empty virus-infected 786-0 cells 
(EV)  with  immunoblot  analysis,  which  showed  a  dramatic  elevation  in  p21  levels  in  the 
YueF-overexpressing  786-0  cells  (Figure  5A).  Consistent  with  the  G1-arrest  phenotype,  the 
YueF-overexpressing cells (pCDH-YueF) showed substantially lower cyclin-D1 and pRB (Ser780) 
levels  compared  to  the  control  cells  (EV),  whereas  there  was  no  change  in  the  CDK2  protein   
levels (Figure 5A). 
To determine whether an elevated p21 level is at least partially responsible for the YueF-induced 
growth  suppression  of  786-0  cells,  we  silenced  p21  expression  in  YueF-overexpressing  786-0   
cells (pCDH-YueF) and empty virus (EV)-infected 786-0 cells with transient transfection of a pool of 
p21-speciﬁc siRNAs and scrambled control siRNA. Western blot data (Figure 5B) confirmed that p21 
expression could be suppressed by p21 siRNA treatment. In contrast, silencing p21 expression led 
to  substantially  faster  growth  of  the  YueF-overexpressing  786-0  cells  (Figure  5C).  The 
YueF-overexpressing  786-0  cell  counts  remained  lower  than  the  corresponding  values  for  the 
EV-infected  cells,  suggesting  that  the  p21  upregulation  is  only  partly  responsible  for  the  growth 
inhibition  of  786-0  cells  induced  by  YueF  overexpression.  Additionally,  silencing  p21  expression 
rescued the G1 arrest induced by YueF overexpression to some extent (Figure 5D). 
Figure 5. YueF overexpression partially inhibits the proliferation of 786-0 cells through 
p21 upregulation. (A) YueF overexpression results in upregulation of p53 and p21 levels, 
but downregulation of cyclin D1 and pRb levels in RCC 786-0 cells; (B) Western blot 
analysis  for  p21  protein  demonstrates  strong  suppression  of  p21  expression  after   
treatment  with  25 nM  of  p21  siRNA;  (C)  Knockdown  of  p21  expression  in 
YueF-overexpressing  (YueF)  and  empty  virus  (EV)-infected  786-0  cells  led  to  a 
substantially faster growth rate in the YueF-overexpressing 786-0 cells; (D) Silencing p21 
expression partially restored the G1 arrest induced by YueF overexpression. (*P < 0.05 
p21 siRNA vs. scramble control; 
#P < 0.05 YueF vs. EV) 
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Figure 5. Cont. 
 
 
4. Discussion 
Although the tumor-suppressive action of YueF in hepatoma cells has been previously reported [5], 
the biological role of YueF and the molecular pathways through which YueF upregulation suppresses 
the growth of renal cell carcinoma (RCC) were not elucidated in earlier studies. YueF is expressed at 
high levels in normal human hepatic cells and tissues, but barely detectable in hepatoma cells and 
tissues. Overexpression of YueF could inhibit cell proliferation, induce cell apoptosis and promote p53 
expression in hepatoma cells, indicating that YueF might be a novel candidate tumor suppressor gene 
involved in hepatocarcinogenesis.   
This study demonstrated that the YueF protein was highly expressed in normal kidney tissues but 
absent or decreased in RCC tissues. It was also expressed at high levels in the normal human renal 
proximal tubular cell line HK2 but was decreased in RCC 786-0 cells. YueF overexpression led to 
increased protein levels of p53 and p21
WAF1/Cip1; the levels of cyclin D1 and pRb were decreased, 
resulting in reduced cell growth and G1/S cell-cycle arrest in vitro. The proliferation defects caused   
by YueF overexpression could be partially rescued by p21 siRNA expression, suggesting that factors 
in  addition  to  p21  upregulation  contribute  to  the  decreased  proliferation  of  YueF-overexpressing   
cells (we also observed a significant decrease in the cyclin D1 level in YueF-overexpressing 786-0 cells). Int. J. Mol. Sci. 2011, 12                         
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Expression of YueF activated p53 expression in both HCC and RCC cells; apoptosis was induced in 
HCC cells, while G1/S cell-cycle arrest was induced in RCC 786-0 cells. Activation of p53 expression 
can trigger various cellular responses that can lead to cell-cycle arrest, senescence, differentiation, 
DNA repair, apoptosis,  and inhibition  of angiogenesis. Furthermore, p53-dependent  transcriptional 
regulation of p21, Cdc25C, and GADD45 has been proposed to mediate cell growth arrest [8–11], and 
the  regulation  of  the  Bcl-2  family  of  proteins  by  p53  mediates  the  mitochondrial  pathway  of 
apoptosis [12]. However, the mechanisms underlying p53-activated cell growth arrest and apoptosis 
are  poorly  understood.  It  has  been  proposed  that  this  process  may  be  driven  by  affinity [13]. 
Low levels  of  stress  or  DNA  damage  could  induce  a  low  level  of  p53  expression  that  causes 
high-affinity growth arrest genes to be upregulated. In contrast, when stress levels are high, induction 
of p53 could be further increased to activate apoptotic genes. Another possibility is that RCC 786-0 
cells are von Hippel-Lindau (VHL) deficient. The expression levels of the pro-apoptotic Bcl-2 family 
protein, BIM-EL, in these cells is low, and therefore, RCC 786-0 cells are more resistant to certain 
apoptotic stimuli than the same cells that stably express the wild-type VHL protein [14,15]. 
The potent cyclin-dependent kinase (CDK) inhibitor, p21 [16], binds to and inhibits the activity of 
CDK4/6-cyclin D complexes. The expression of p21 is strictly controlled by the tumor suppressor 
protein p53, which mediates the p53-dependent G1 phase of the cell cycle [17]. The retinoblastoma 
tumor suppressor gene (pRb) is a substrate of CDK4/6-cyclin D. When a cell prepares to enter S phase, 
complexes  of CDK4/6-cyclin  D  phosphorylate  pRb  and  inhibit  its  activity;  E2F  transcription   
factors  [18,19] are positively  regulated and induce S phase  entry. The phosphorylation of pRb is 
inhibited  by  p21,  resulting  in  the  negative  regulation  of  E2F  transcription  factors  and  cell-cycle 
G1 phase arrest. In the present study, it was found that YueF stimulates p53 transcriptional activity and 
mediates  G1  cell-cycle  arrest  through  the  upregulation  of  p21,  repression  of  cyclin  D1,  and 
dephosphorylation of pRb. 
Here,  we  observed  that  the  level  of  pRb,  which  is  a  CDK  substrate,  was  decreased  in 
YueF-overexpressing cells, whereas CDK2 levels did not show any change. Generally, p21 not only 
inhibits  the  activity  of CDK4/6-cyclin  D complexes  and  induces  G1  phase  arrest  but  also  inhibits 
cyclin E/CDK2 complexes and entry into S phase. CDK protein levels always remain stable, whereas 
the levels of cyclins fluctuate periodically during the cell cycle [20]. CDK2 activity is not associated 
with CDK2 protein levels. There are at least four major mechanisms involved in the inactivation of 
CDK2 kinase: dephosphorylation of Thr160, phosphorylation of Thr14 and Tyr15, removal of cyclin 
E, and binding of cyclin-dependent kinase inhibitors (CKI) [21]. Some reports have also shown that 
CDK2 activity can be decreased without suppressing CDK2 protein levels [22,23]. 
The  mechanism  by  which  YueF  overexpression  activates  p53  remains  unknown.  Huang  et  al. 
showed [5] that YueF overexpression enhanced p53 promoter activity in HepG2 hepatoma cells. YueF 
was initially identified as a Hepatitis B virus X protein (HBx)-interacting protein. HBx inhibits p53 
promoter activity and protein expression, while YueF overrides the function of HBx by promoting p53 
protein expression in hepatoma cells, suggesting that YueF is a strong antagonist of the p53 negative 
regulator. Murine double minute 2 (MDM2), a key negative regulator of p53 stability and activity, can 
bind  to  p53  and  block  p53  transcriptional  activity [24].  YueF  may  also  interact  with  MDM2  and 
upregulate p53 expression; however, this hypothesis requires further investigation. Int. J. Mol. Sci. 2011, 12                         
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5. Conclusion 
Here, we report the first investigation of how YueF upregulation alters the cell-cycle progression of 
786-0 cells. We observed the downregulation of YueF in RCC tissues and 786-0 cells. We further 
present  the  novel  ﬁndings  that  YueF  overexpression  in  786-0  cells  is  associated  with  a  dramatic 
upregulation of p21 levels, cell-cycle arrest at the G1 phase, and reduced cell proliferation in vitro. 
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